All In Biotech

Drug Trial Radar · NCT07119372

Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

A Randomized, Open-label, Comparative Clinical Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 228 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

228

Planned (sponsor's estimate)

Start

Mar 1, 2025

Primary completion

May 12, 2026

Study completion Oct 2027

Sponsor

Lead sponsor
BiocadIndustry
Sponsor type
Industry
First posted
Aug 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

BCD-131 is pegylated darbepoetin beta. This clinical study BCD-131-3 is a randomized, open-label, phase III study of the efficacy and safety of BCD-131 and Mircera used for the treatment of anemia in end-stage chronic kidney disease (CKD) patients on dialysis.

Conditions

  • Anemia
  • Chronic Kidney Disease
  • Chronic Kidney Disease Patients on Hemodialysis
  • Chronic Kidney Disease 5D

Interventions

  • BCD-131 (pegdarbepoetin beta)Biological

    BCD-131 (pegdarbepoetin beta), subcutaneous injection; regimen: once every 4 weeks; therapy duration: 84 weeks

  • Mircera (methoxypolyethylene glycol-epoetin beta)Biological

    Mircera (methoxypolyethylene glycol-epoetin beta), subcutaneous injection; regimen: once every 4 weeks up to Week 48 inclusive; starting from Week 52, all subjects will be switched to BCD-131 treatment up to Week 84 inclusive.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects (%) with the target hemoglobin level (100-120 g/L inclusive)Time frame: During the assessment period at Weeks 28-32

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Limited Liability Company "Medical Center "NEFROS"

    Krasnodar, Russia

  • Limited Liability Company Medical Center "NEPHROS"

    Krasnodar, Russia

  • Limited Liability Company "Nephroline-Sibir"

    Novosibirsk, Russia

  • State Autonomous Healthcare Institution Orenburg Regional Clinical Center of Surgery and Traumatology

    Orenburg, Russia

  • "All-Russian Center for Emergency and Radiation Medicine named after A.M. Nikiforov" of the Ministry of Emergency Situations of the Russian Federation

    Saint Petersburg, Russia

  • Limited Liability Company "Kupchinsky Outpatient Dialysis Center"

    Saint Petersburg, Russia

  • Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin

    Saint Petersburg, Russia

  • Saint Petersburg State Budgetary Healthcare Institution "City Clinical Hospital No. 31"

    Saint Petersburg, Russia

  • Saint Petersburg State Budgetary Healthcare Institution "S.P. Botkin Clinical Infectious Diseases Hospital"

    Saint Petersburg, Russia

  • St. Petersburg City Hospital No. 26

    Saint Petersburg, Russia

  • State Budgetary Healthcare Institution "Volgograd Regional Uronephrological Center"

    Volgograd, Russia

  • Limited Liability Company "Medical Diagnostic Center"

    Yaroslavl, Russia

  • Limited Liability Company "FAMILY CLINIC"

    Yekaterinburg, Russia

  • Sverdlovsk Regional Clinical Hospital No. 1

    Yekaterinburg, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.